University of Queensland researchers are taking up the fight against one of the deadliest forms of breast cancer, developing next-generation nanoparticles to supercharge current treatments for triple-negative breast cancer.
AIBN researchers scored four wins in the latest Investigator Grant round for nanotechnology projects that could change the way we approach certain diseases.
AIBN researchers want HIV patients to have the option of taking a long-acting antiretroviral dose once a week, instead of having to take a dose every day.
Two rising research stars have shown just why the AIBN is renowned as an incubator for scientific talent, each securing $440,000 funding to accelerate their game-changing work.
Colorectal cancer (CRC) is one of the most common and lethal tumours worldwide. Current therapies are often unsuccessful because CRC frequently recurs with metastasis after treatment cessation.
Medication adherence is required for the effectiveness of all pharmacotherapies, especially for long-term treatment of chronic illness and infectious diseases.
Two projects led by AIBN researchers – and another that features some of our brightest minds – have been recognised with $2m funding under the latest ARC Linkage Grants round.
In addition to utilising nanoparticles as immunoadjuvant to activate immune systems, Jie has also demonstrated that rationally designed nanoparticles are able to modulate the death modality of cancer cells in a manner that can alert immune systems and generate an anti-cancer adaptive immune response.
